Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Intercept Commits To Resubmitting NASH NDA, But Analysts See Conflicting Signs
Feb 25 2021
•
By
Joseph Haas
Analysts wonder if Intercept is de-emphasizing NASH to focus on PBC
More from Strategy
More from Business